DRTS - Alpha Tau director gives up board seat to take up chief commercial officer role
- Alpha Tau Medical ( NASDAQ: DRTS ) appointed Peter Melnyk as Chief Commercial Officer (CCO).
- Melnyk resigned from Alpha's board to assume the full-time position as CCO, the Israeli cancer drug company said in a Sept. 1 press release.
- Melnyk most recently served as CEO of Fortovia Therapeutics, a Raleigh, N.C.-based oncology supportive care pharmaceutical and medical device company. Prior to that Melnyk served as CCO of Novocure.
- "As we continue to progress rapidly towards securing further marketing approvals for the Alpha DaRT, and with our U.S. pivotal multi-center study in recurrent squamous cell carcinoma expected to commence shortly, it is a perfect time to bolster our senior management team with someone of Peter’s caliber who will be dedicated to advancing our global commercial strategies," said Alpha CEO Uzi Sofer.
For further details see:
Alpha Tau director gives up board seat to take up chief commercial officer role